35 Background: Sarcopenia is a complex and multifactorial geriatric condition seen in 36 several chronic degenerative diseases. This study aimed to screen for sarcopenia and fall 37 risk in a sample of Parkinson's disease (PD) patients and to investigate demographic 38 and clinical factors associated.
133
The diagnosis of sarcopenia was based on EWGSOP criteria [9] . The diagnosis 134 of probable sarcopenia was confirmed by screening positive in the SARC-F (score ≥4)
135 and the presence of low muscle strength measured by the hand grip strength test and/or 136 FTSTS. All patients were evaluated for disease staging (modified HY scale), quality of 137 life, lower extremity strength (SARC-F) and strength during "on" phases. For numerical variables, data were presented as means, standard deviations and 147 medians. For categorical variables, data were described as frequencies and prevalence 148 rates to investigate associations between risk factors and probable sarcopenia and falls 149 in the prior six months. For the analysis of the participants' characteristics, we used the 150 Mann-Whitney U-test because independent variables were not normally distributed. To 151 investigate the association between categorical variables, we used Pearson's chi-square 152 and Fisher's exact tests. Logistic regression models including probable sarcopenia and 153 falls in prior 6 months as outcomes were adjusted for the variables with p < 0.05 in the 154 bivariate analysis.
155
A significance level of 5% was adopted. Statistical analyses were performed 156 using the JAMOVI statistical software (Version 0.9).
RESULTS

159
Associations with probable sarcopenia
160
The study population was composed of a total of 218 patients, of which 93 161 (42.7%) were women. The mean age was 67.2 ± 10.9 years and mean disease duration 162 was 9.4 ± 6.9 years. One hundred and twenty-one patients (55.5%) screened positive 163 for sarcopenia using the SARC-F and 103 (47.4%) met the criteria for probable
164 sarcopenia. 
189
The following variables with p < 0.05 in the bivariate analysis were included in 190 the logistic regression models: gender, falls in the prior 6 months, osteoporosis, 191 modified HY stage, SE ADL score, LED, disease duration and PDQ-39 score. These 192 variables were included in the logistic regression models in a stepwise forward manner.
193 Female gender, modified HY stage and PDQ-39 score were independently significantly 194 associated with probable sarcopenia (Table 2) . Associations with falls in the prior six months
196
204
Disease duration, modified HY stage, SE ADL score, LED, probable sarcopenia 205 and positive SARC-F (SARC-F+) were associated with falls in the prior six months 206 with p < 0.05 in the bivariate analysis (Table 3) .
207
208 These variables were included in the stepwise forward logistic regression 221 models. Table 4 shows that only SARC-F+ and disease duration were independently 222 associated with falls in the prior six months in our study. The association between 223 positive SARC-F and occurrence of falls in the prior six months is also illustrated in 224 Figure 1 .
225 
253
To date, few studies have assessed the prevalence of sarcopenia in PD patients, 254 with reports ranging from 6% to 55.8% [18] [19] [20] [21] . It should be noted that the prevalence 255 of sarcopenia varies greatly due to the use of different definitions and diagnostic tools 256 as well as patient selection methods. However, these data are of great relevance given 257 the increased risk of adverse outcomes associated with sarcopenia in the older adults 258 such as falls, fractures and impaired ability to perform ADL [9], which are also 259 important issues when managing PD patients.
260
Patients with probable sarcopenia and falls in the prior 6 months show higher 261 modified HY and lower SE ADL scores. Moreover, they take higher LED and use a 262 greater number of medications. It has been shown that older people with 263 antiparkinsonian drugs are at higher risk of being exposed to fall-risk inducing drugs 
312
The present study has some limitations. Firstly, we excluded patients who were 313 wheelchair users. Therefore, the prevalence of sarcopenia may have been 346 ACKNOWLEDGMENTS
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